Registry-listed formulations

acebilustat · mesh:C000625351

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    67%(2 trials)

    Phase Distribution

    Phase 2
    3
    100%

    Phase Distribution

    0

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 2Efficacy & side effects
    3(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(3)

    Detailed Status

    Completed3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 23 (100.0%)

    Trials by Status

    completed3100%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_2

    A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema

    NCT05203835
    completedphase_2

    COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

    NCT04662086
    completedphase_2

    COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

    NCT04662060

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT05203835Phase 2

    A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema

    Completed
    NCT04662086Phase 2

    COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

    Completed
    NCT04662060Phase 2

    COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    3

    External References

    ChEMBL
    CHEMBL4297604

    Names & Codes

    Research Codes

    Ctx-4430EP-501